Back to results
US 2022/0119347 A1Published application
Biaryl compositions in combination with tamoxifen and methods for modulating a kinase cascade
AssigneeAthenex, Inc.
InventorDavid G. HANGAUER, JR.
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
Claims3
Use of a compound according to Formula IB:
- or a salt, solvate, hydrate, or prodrug thereof,
- wherein:
- T is a bond;
- Xy is CY, N, or N—O;
- Xz is CZ;
- Y is selected from hydrogen, hydroxyl, halogen, lower (C1, C2, C3, C4, C5, or C6) alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, and O-benzyl;
- Xa is CRa or N, or N—O;
- Xb is CRb, N, or N—O;
- Xc is CRc or N, or N—O;
- Xd is CRd or N, or N—O;
- Xe is CRe, N, or N—O;
- Ra, Rb, Rc, Rd, Re, R4, R5, and R6 are, independently, hydrogen, hydroxyl, halogen, P, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, SO2-lower (C1, C2, C3, C4, C5, or C6) alkyl,
- where W is H, or C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkyl-aryl;
- P is SO3H, OSO3H, OPO3H2, OPO3H2, NH2, NHR19, NHR20R21,
- tetrazole, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-K, O—C(O)-lower (C1, C2, C3, C4, C5, or C6) alkyl-L, NH-lower (C1, C2, C3, C4, C5, or C6) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
- K is C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- L is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- M is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- Q is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- R19, R20 and R21 are C1, C2, C3, C4, C5, or C6 alkyl or R19 and R20 taken together with the attached nitrogen atom form a five membered ring;
- V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2— or —OCH2CH2CH2—;
- R12, R13, R14, R15, R16, R17, and R18, are, independently, H or C1, C2, C3, C4, C5, or C6 alkyl;
- Z is (CHR1)n—C(O)—NR2(CHR3)m—Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R1, R2, and R3 are independently H or C1, C2, C3, C4, C5, or C6 alkyl;
- and
- n and m are independently 0, 1, or 2,
- in the manufacture of a medicament for treating or preventing cancer, wherein the cancer is selected from renal, liver, or brain cancer.
23 more elements
-19. (canceled)
A composition comprising tamoxifen and a compound of Formula I:
- or a salt, solvate, hydrate, or prodrug thereof,
- wherein:
- T is a bond, CR12R13, C(O), O, S, S(O), S(O)2, NR14, C(R15R16)C(R17R18), CH2O, or OCH2;
- Xy is CZ, CY, N, or N—O;
- Xz is CZ, CY, N, or N—O;
- at least one of Xy and Xz is CZ;
- Y is selected from hydrogen, hydroxyl, halogen, lower (C1, C2, C3, C4, C5, or C6) alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, and O-benzyl;
- Xa is CRa or N, or N—O;
- Xb is CRb, N, or N—O;
- Xc is CRc or N, or N—O;
- Xd is CRd or N, or N—O;
- Xe is CRe, N, or N—O;
- Ra, Rb, Rc, Rd, Re, R4, R5, and R6 are, independently, hydrogen, hydroxyl, halogen, P, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, SO2-lower (C1, C2, C3, C4, C5, or C6) alkyl,
- where W is H, or C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkyl-aryl;
- P is SO3H, OSO3H, OPO3H2, OPO3H2, NH2, NHR19, NHR20R21,
- tetrazole, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-K, O—C(O)-lower (C1, C2, C3, C4, C5, or C6) alkyl-L, NH-lower (C1, C2, C3, C4, C5, or C6) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
- K is C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- L is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- M is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- Q is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- R19, R20 and R21 are C1, C2, C3, C4, C5, or C6 alkyl or R19 and R20 taken together with the attached nitrogen atom form a five membered ring;
- V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2— or —OCH2CH2CH2—;
- R12, R13, R14, R15, R16, R17, and R18, are, independently, H or C1, C2, C3, C4, C5, or C6 alkyl;
- Z is (CHR1)n—C(O)—NR2(CHR3)m—Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R1, R2, and R3 are independently H or C1, C2, C3, C4, C5, or C6 alkyl;
- and
- n and m are independently 0, 1, or 2.
23 more elements
Dependencies are inferred from the claim text.